Fighting physics: a tough battle

Jonathan M. Smith

DOI: https://doi.org/10.1145/1538788.1538806

2009-04-01

Abstract:The laws of physics and the Internet's routing infrastructure affect performance in a big way.

What problem does this paper attempt to address?

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment

Marc Gutierrez,Patrick Bladek,Busra Goksu,Carlos Murga-Zamalloa,Dale Bixby,Ryan Wilcox

DOI: https://doi.org/10.3390/ijms241512106

2023-07-28

Abstract:T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells. Most patients with T-PLL present with lymphocytosis, anemia, thrombocytopenia, and hepatosplenomegaly. Correct identification of T-PLL is essential because treatment for this disease is distinct from that of other T-cell neoplasms. In 2019, the T-PLL International Study Group (TPLL-ISG) established criteria for the diagnosis, staging, and assessment of response to treatment of T-PLL with the goal of harmonizing research efforts and supporting clinical decision-making. T-PLL pathogenesis is commonly driven by T-cell leukemia 1 (TCL1) overexpression and ATM loss, genetic alterations that are incorporated into the TPLL-ISG diagnostic criteria. The cooperativity between TCL1 family members and ATM is seemingly unique to T-PLL across the spectrum of T-cell neoplasms. The role of the T-cell receptor, its downstream kinases, and JAK/STAT signaling are also emerging themes in disease pathogenesis and have obvious therapeutic implications. Despite improved understanding of disease pathogenesis, alemtuzumab remains the frontline therapy in the treatment of naïve patients with indications for treatment given its high response rate. Unfortunately, the responses achieved are rarely durable, and the majority of patients are not candidates for consolidation with hematopoietic stem cell transplantation. Improved understanding of T-PLL pathogenesis has unveiled novel therapeutic vulnerabilities that may change the natural history of this lymphoproliferative neoplasm and will be the focus of this concise review.
T-cell prolymphocytic leukemia: a single-institution experience

Farhad Ravandi,Susan O'Brien,Dan Jones,Susan Lerner,Stefan Faderl,Alessandra Ferrajoli,William Wierda,Guillermo Garcia-Manero,Deborah Thomas,Charles Koller,Srdan Verstovsek,Francis Giles,Jorge Cortes,Marco Herling,Hagop Kantarjian,Michael Keating

DOI: https://doi.org/10.3816/CLM.2005.n.051

Abstract:Background: T-cell prolymphocytic leukemia is an uncommon, aggressive, mature T-cell leukemia characterized by proliferation of T-cell lymphocytes. The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias. Patients and methods: The clinical, pathologic, and cytogenetic features of 57 patients with T-PLL who were evaluated at the Department of Leukemia, M. D. Anderson Cancer Center (MDACC) from 1986 to 2004 were examined. Results: The most common cytogenetic abnormality was inv(14)(q11;q32), which was present in 7 patients. In all 7 patients, this abnormality was associated with other chromosomal aberrations. Patients treated with alemtuzumab at MDACC had a significantly better response rate (P = 0.02) and survival rate (P = 0.002). There were no significant differences in survival based on Tcl-1 expression or different patterns of CD4 and CD8 expression. Conclusion: Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.
Factors influencing protein tyrosine nitration--structure-based predictive models.

Alexander S. Bayden,V. Yakovlev,P. Graves,R. Mikkelsen,G. Kellogg

DOI: https://doi.org/10.1016/j.freeradbiomed.2010.12.016

2011-03-15

Abstract:
Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene

Siyu Sun,Wenjia Fang

DOI: https://doi.org/10.1016/j.biopha.2020.110107

Abstract:T-cell prolymphocytic leukemia (T-PLL) is a rare mature T cell leukemia with aggressive clinical course, poor response to conventional therapies and high mortality rates. Classical cytogenetics and various genetic techniques have observed complex karyotypes and associated genes involved in the molecular pathogenesis of T-PLL, among which the proto-oncogene T-cell leukemia/lymphoma 1 (TCL1) as a hallmark of malignancy is hyper-activated and abnormally expressed in many T-PLL cases. Progress has been made to identify the presence of chromosomal rearrangements and subsequent changes in key molecular pathways typically involving Akt, which may hint cytogenetic mechanisms underlying the pathogenesis of T-PLL and indicate new treatment targets. In this article, we describe current insights of T-PLL with an emphasis on the potential role of TCL1 gene disorders and TCL1-Akt interactions in cell transformation and disease progression, followed by discussion on current treatment options and novel therapeutic approaches based on cytogenetics, which still remains to be explored for the effective management of T-PLL and other TCL1-driven hematological malignancies.
T‐cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments

Victoria A. Vardell,Daniel A. Ermann,Lindsey Fitzgerald,Harsh Shah,Boyu Hu,Deborah M. Stephens

DOI: https://doi.org/10.1002/ajh.27205

IF: 13.265

2024-01-20

American Journal of Hematology

Abstract:Survival remains poor for T‐cell prolymphocytic leukemia, though treatment in recent years, associated with access to novel therapies, and management at academic medical centers is associated with improved outcomes. There remains a critical need to improve the available treatment options for this population, and access to specialized academic medical centers, comprehensive supportive care, clinical trials, and early palliative care remains essential for T‐PLL patients.

hematology
From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature

Karen A Nahmod,Beenu Thakral,F N U Aakash,Swaminathan P Iyer,L Jeffrey Medeiros,Andres E Quesada

DOI: https://doi.org/10.1016/j.anndiagpath.2022.152077

Abstract:T-prolymphocytic leukemia (T-PLL) is a rare, aggressive T-cell leukemia, and patients typically present with marked peripheral blood lymphocytosis. Approximately 15-20 % of patients may present with moderate and relative stable lymphocytosis and an indolent clinical course that can persist for a few years. However, eventually these patients go on to develop marked lymphocytosis and rapidly progressive disease. We report a 72-year-old man who presented with multicompartmental lymphadenopathy and a normal complete blood count. Excision of left and right cervical lymph nodes showed replacement of the lymph node architecture by a small T-cell neoplasm positive for CD3, CD4, CD5, CD7 and TCL-1, and negative for CD8, CD20, CD30 and ALK. Subsequent bone marrow evaluation showed minimal bone marrow involvement by a T-cell neoplasm associated with TCL1A rearrangement in 11 % of cells supporting the diagnosis of T-PLL. Despite treatment, he showed progressive lymphadenopathy while remarkably maintaining normal white blood cell counts until he eventually developed leukocytosis of 110.9 × 103/uL 26 months later. Review of the literature identified only a single abstract reporting a patient with a similar lymphoma-like presentation and normal white blood cell count; however, that case showed significant bone marrow involvement in stark contrast to the current case. In summary, we report a highly unusual case of T-PLL can initially presenting with an aleukemic or lymphoma-like clinical picture, which can make establishing the diagnosis challenging.
EMT domestic violence knowledge and the results of an educational intervention.

S. Weiss,A. Ernst,D. Blanton,D. Sewell,T. Nick

DOI: https://doi.org/10.1016/S0735-6757(00)90011-1

2000-03-01

Abstract:
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia

Paurnima Patil,Agata Cieslak,Stephan H Bernhart,Umut H Toprak,Rabea Wagener,Cristina López,Laura Wiehle,Susanne Bens,Janine Altmüller,Marek Franitza,Ingrid Scholz,Sandrine Jayne,Matthew J Ahearne,Annika Scheffold,Billy M C Jebaraj,Christof Schneider,Dolors Costa,Till Braun,Alexandra Schrader,Elias Campo,Martin J S Dyer,Peter Nürnberg,Jan Dürig,Patricia Johansson,Sebastian Böttcher,Matthias Schlesner,Marco Herling,Stephan Stilgenbauer,Elizabeth Macintyre,Reiner Siebert

DOI: https://doi.org/10.1002/gcc.22821

Abstract:T-cell prolymphocytic leukemia (T-PLL) is an aggressive tumor with leukemic presentation of mature T-lymphocytes. Here, we aimed at characterizing the initial events in the molecular pathogenesis of T-PLL and particularly, at determining the point in T-cell differentiation when the hallmark oncogenic events, that is, inv(14)(q11q32)/t(14;14)(q11;q32) and t(X;14)(q28;q11) occur. To this end, we mined whole genome and transcriptome sequencing data of 17 and 11 T-PLL cases, respectively. Mapping of the 14q32.1 locus breakpoints identified only TCL1A, which was moreover significantly overexpressed in T-PLL as compared to benign CD4+ and CD8+ T-cells, as the only common oncogenic target of aberrations. In cases with t(14;14), the breakpoints mapped telomeric and in cases with inv(14) centromeric or in the 3'-untranslated region of TCL1A. Regarding the T-cell receptor alpha (TRA) locus-TCL1A breakpoint junctions, all 17 breakpoints involved recombination signal sequences and 15 junctions contained nontemplated (N-) nucleotides. All T-PLL cases studied carried in-frame TRA rearrangements on the intact allele, which skewed significantly toward usage of distal/central TRAV/TRAJ gene segments as compared to the illegitimate TRA rearrangements. Our findings suggest that the oncogenic TRA-TCL1A/MTCP1 rearrangements in T-PLL occur during opening of the TRA locus, that is, during the progression from CD4+ immature single positive to early double positive thymocyte stage, just before physiologic TCL1A expression is silenced. The cell carrying such an oncogenic event continues maturation and rearranges the second TRA allele to achieve a functional T-cell receptor. Thereafter, it switches off RAG and DNTT expression in line with the mature T-cell phenotype at presentation of T-PLL.
Diverse two-cysteine photocycles in phytochromes and cyanobacteriochromes

N. Rockwell,Shelley S. Martin,K. Feoktistova,J. Lagarias

DOI: https://doi.org/10.1073/pnas.1107844108

2011-06-28

Abstract:Phytochromes are well-known as photoactive red- and near IR-absorbing chromoproteins with cysteine-linked linear tetrapyrrole (bilin) prosthetic groups. Phytochrome photoswitching regulates adaptive responses to light in both photosynthetic and nonphotosynthetic organisms. Exclusively found in cyanobacteria, the related cyanobacteriochrome (CBCR) sensors extend the photosensory range of the phytochrome superfamily to shorter wavelengths of visible light. Blue/green light sensing by a well-studied subfamily of CBCRs proceeds via a photolabile thioether linkage to a second cysteine fully conserved in this subfamily. In the present study, we show that dual-cysteine photosensors have repeatedly evolved in cyanobacteria via insertion of a second cysteine at different positions within the bilin-binding GAF domain (cGMP-specific phosphodiesterases, cyanobacterial adenylate cyclases, and formate hydrogen lyase transcription activator FhlA) shared by CBCRs and phytochromes. Such sensors exhibit a diverse range of photocycles, yet all share ground-state absorbance of near-UV to blue light and a common mechanism of light perception: reversible photoisomerization of the bilin 15,16 double bond. Using site-directed mutagenesis, chemical modification and spectroscopy to characterize novel dual-cysteine photosensors from the cyanobacterium Nostoc punctiforme ATCC 29133, we establish that this spectral diversity can be tuned by varying the light-dependent stability of the second thioether linkage. We also show that such behavior can be engineered into the conventional phytochrome Cph1 from Synechocystis sp. PCC6803. Dual-cysteine photosensors thus allow the phytochrome superfamily in cyanobacteria to sense the full solar spectrum at the earth surface from near infrared to near ultraviolet.
A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia

Ozgur Can Eren,Robert Stuver,Ting Zhou,Michael Zaidinski,Alison J. Moskowitz,Steven M. Horwitz,Mark D. Ewalt,Yanming Zhang,Megan S. Lim

DOI: https://doi.org/10.1002/gcc.23252

2024-06-24

Genes Chromosomes and Cancer

Abstract:T‐cell prolymphocytic leukemia (T‐PLL) is a rare and aggressive mature T‐cell malignancy characterized by marked lymphocytosis, B symptoms, lymphadenopathy, and hepatosplenomegaly. There is no standard treatment approach, and in the absence of an allogeneic transplant, the prognosis remains poor. The disease‐defining cytogenetic abnormality in T‐PLL is the juxtaposition of the TCL1‐family oncogene to the TCR gene enhancer locus primarily due to an inversion of chromosome 14, that is, inv(14). The application of next‐generation sequencing technologies led to the discovery of highly recurrent gain‐of‐function mutations in JAK1/3 and STAT5B in over 70% of T‐PLL providing opportunities for therapeutic intervention using small molecule inhibitors. Additional genetic mechanisms that may contribute to the pathogenesis of T‐PLL remain unknown. Herein we describe the identification of a novel gene fusion SMCHD1::JAK2 resulting from a translocation between chromosome 9 and 18 involving SMCHD1 exon 45 and JAK2 exon 14 (t(9;18)(p24.1;p11.32)(chr9:g.5080171::chr18:g.2793269)), a previously undescribed genetic event in a patient with T‐PLL harboring the key disease defining inv(14) resulting in rearrangement of TCL1 and TRA/D. In this manuscript, we describe the clinical and genetic features of the patient's disease course over a 25‐month post‐treatment duration using ruxolitinib and duvelisib.

oncology,genetics & heredity
The construction, calibration and use of thermocouples for measuring body temperature.

W. W. Tuttle,C. D. Janney

IF: 4.06

Archives of Physical Medicine and Rehabilitation

Abstract:
Chemoprophylaxis of dental patients with prosthetic joints: a simulation model.

JJ Jacobson,S. Schweitzer,DJ DePorter,JJ Lee

DOI: https://doi.org/10.1002/J.0022-0337.1988.52.11.TB02251.X

1988-11-01

Journal of Dental Education

Abstract:A computer simulation model was created to assess the risks and effects of no prophylaxis, oral penicillin, and oral cephalexin regimens for dental patients at risk for late prosthetic joint infection (LPJI). Given the assumptions made, this analysis suggests that there is a very small risk of LPJI (29-68 cases per 10(6) dental visits), which is outweighed by a greater risk of death from a fatal antibiotic reaction. Thus, routine predental antibiotic prophylaxis for all dental patients with prosthetic joints may lead to higher mortality. However, clinical experience suggests that antibiotic prophylaxis may be appropriate in "high risk" patients.
TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy

Zhihong Hu,Shaoying Li,L Jeffrey Medeiros,Tsieh Sun

DOI: https://doi.org/10.1016/j.humpath.2016.12.030

Abstract:T-prolymphocytic leukemia (T-PLL) is a rare mature T-cell neoplasm characterized by proliferation of prolymphocytes. Most cases involve the T-cell leukemia-1 (TCL1) gene at 14q11.2 resulting in overexpression of TCL-1, which is helpful for distinguishing T-PLL from other T-cell neoplasms. We report a patient with T-PLL whose leukemic cells were positive for TCL-1 by immunohistochemistry but with a normal karyotype. The patient had anti-CD52 antibody therapy for 12 weeks. In a follow-up bone marrow biopsy specimen, numerous TCL-1-positive cells were present, which raised the differential diagnosis of residual T-PLL. However, further immunophenotypic studies confirmed that these cells were hematogones. Therefore a diagnosis of recovering bone marrow was established. The patient underwent stem cell transplant and is now in complete remission. This case demonstrates that hematogones can express TCL-1, and this knowledge is very important for the differential diagnosis in the follow-up marrow of T-PLL patients.
Effect of the M(s) transformation temperature on the wear behaviour of NiTi shape memory alloys for articular prosthesis.

J. Peña,E. Solano,A. Mendoza,J. Casals,J. Planell,F. Gil

Bio-Medical Materials and Engineering

Abstract:The main objective of this work has been the characterisation and correlation of the wear behaviour of the NiTi shape memory alloys in their different phases. The weight losses for the different alloys in function of the present phase, and of the M(s) transformation temperature are studied. Adhesive wear tests, Pin-on-Disk, according to the ASTM-G99 standard have been carried out. The thermoelastic martensitic transformations that cause the super-elastic effect, the reorientation and coalescence of martensitic plates and the damping effect promotes a high ability to accommodate large deformations without generating permanent damages that causes the wear. The resulting plastic deformation may be accumulated during wear process without generating fracture. The results show that the wear resistance is mainly dependent of the M(s) transformation temperature for both alloys. For the NiTi alloys also the Ni atomic percentage and the hardness of the alloys are important parameters in the wear behavior.
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia

Zhihong Hu,L Jeffrey Medeiros,Lianghua Fang,Yi Sun,Zhenya Tang,Guilin Tang,Tsieh Sun,Andres E Quesada,Shimin Hu,Sa A Wang,Lin Pei,Xinyan Lu

DOI: https://doi.org/10.1002/ajh.24679

Abstract:T-cell prolymphocytic leukemia (T-PLL) is an aggressive mature T-cell neoplasm. The most common cytogenetic abnormality associated with T-PLL is inv(14)(q11.2q32) involving TCL1, but other abnormalities also have been reported. In this study, we correlated cytogenetic abnormalities with clinical outcome in 97 T-PLL patients, including 66 men and 31 women with a median age of 63 years (range, 34-81). Twenty-seven patients had a normal karyotype (NK), one had two chromosomal aberrations, and 69 had a complex karyotype (CK). Patients with a CK had poorer overall survival (OS) than patients with a NK (P = .0016). In the CK group, the most common aberrations involved 14q (n = 45) and 8q (n = 38). Additional deletions of chromosomes 17p, 11q, 6q, 12p, 13q were observed frequently. No individual cytogenetic abnormality impacted OS. Patients with ≥5 aberrations had an OS of 11 months versus 22 months in patients with <5 aberrations (P = 0.0132). Fluorescence in situ hybridization for TCL1 successfully performed in 27 cases showed rearrangement in 8/10 (80%) NK versus 16/17 (94%) CK cases. OS of patients with TCL1 rearrangement and/or 14q aberrations was not significantly different from patients without TCL1 rearrangement and 14q aberrations (P = .3467). Patients with refractory disease showed worse OS in both the NK and CK groups (P = .0014 and P < .0001, respectively), compared with patients who achieved remission but then relapsed. Stem cell transplantation did not appear to improve OS regardless of karyotype complexity. In conclusion, patients with T-PLL often have a CK which is a poor prognostic factor, particularly in patients with ≥5 cytogenetic aberrations.
Toward novel antiparasitic formulations: Complexes of Albendazole desmotropes and β-cyclodextrin.

A. Chattah,Laura Y. Pfund,A. Zoppi,M. Longhi,C. Garnero

DOI: https://doi.org/10.1016/j.carbpol.2017.01.098

IF: 10.723

2017-05-15

Carbohydrate Polymers

Abstract:
Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia

Cristina López,Anke K Bergmann,Ulrike Paul,Eva M Murga Penas,Inga Nagel,Matthew J Betts,Patricia Johansson,Matthias Ritgen,Tycho Baumann,Marta Aymerich,Sandrine Jayne,Robert B Russell,Elias Campo,Martin J S Dyer,Jan Dürig,Reiner Siebert

DOI: https://doi.org/10.1111/bjh.13952

Abstract:T-cell prolymphocytic leukaemia (T-PLL) is an aggressive leukaemia. The primary genetic alteration in T-PLL are the inv(14)(q11q32)/t(14;14)(q11;q32) leading to TRD/TRA-TCL1A fusion, or the t(X;14)(q28;q11) associated with TRD/TRA-MTCP1 fusion. However, additional cooperating abnormalities are necessary for emergence of the full neoplastic phenotype. Though the pattern of secondary chromosomal aberrations is remarkably conserved, targets of the changes are largely unknown. We analysed a cohort of 43 well-characterized T-PLL for hotspot mutations in the genes JAK3, STAT5B and RHOA. Additionally, we selected a subset of 23 T-PLL cases for mutational screening of 54 genes known to be recurrently mutated in T-cell and other haematological neoplasms. Activating mutations in the investigated regions of the JAK3 and STAT5B genes were detected in 30% (13/43) and 21% (8/39) of the cases, respectively, and were mutually exclusive. Further, we identified mutations in the genes encoding the epigenetic regulators EZH2 in 13% (3/23), TET2 in 17% (4/23) and BCOR in 9% (2/23) of the cases. We confirmed that the JAK-STAT pathway is a major mutational target, and identified epigenetic regulators recurrently mutated in T-PLL. These findings complement the mutational spectrum of secondary aberrations in T-PLL and underscore the potential therapeutical relevance of epigenetic regulators in T-PLL.
Does a subset of mature T-cell leukemias with features akin to T-cell prolymphocytic leukemia but lacking rearrangement of the TCL1 represent peripheral T-cell lymphoma, NOS in a leukemic phase?

David C Gajzer,Xueyan Chen,Daniel E Sabath,Christina Poh,Kikkeri N Naresh

DOI: https://doi.org/10.1002/jha2.953

2024-06-17

eJHaem

Abstract:In the current WHO classification, a T-cell prolymphocytic leukemia (T-PLL) diagnosis requires lymphocytosis of >5 × 109/L, evidence of monoclonality, and TCL1A or MTCP1 rearrangement. However, the 2019 consensus document suggested that in the absence of rearrangement of TCL1-family, the presence of abnormalities involving chromosome 11 (11q22.3; ATM), chromosome 8 (idic(8)(p11), t(8;8), trisomy 8q), 5, 12, 13, 22, or a complex karyotype, as well as involvement specific sites (e.g., splenomegaly, effusions) would suffice for a diagnosis of T-PLL. We present a patient diagnosed with T-PLL with MTCP1 rearrangement who was successfully treated with alemtuzumab followed by consolidative allogeneic unrelated donor stem cell transplantation. Eight years later, the patient presented with inguinal lymphadenopathy with features more akin to peripheral T-cell lymphoma, NOS (PTCL, NOS) of the GATA3 subtype, and there was no evidence of peripheral blood involvement. However, the lymphoma cells were clonally related to those at presentation. Currently, literature on T-PLL-like cases lacking the rearrangement of TCL1A is limited, and the possibility of whether a proportion of such cases could represent PTCL, NOS (with leukemic involvement) needs consideration.
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

Michael Hallek

DOI: https://doi.org/10.1002/ajh.25595

IF: 13.265

2019-10-04

American Journal of Hematology

Abstract:DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that impair apoptosis of clonal B-cells.DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen, as well as typical B-cell markers.PROGNOSIS: The two similar clinical staging systems, Rai and Binet, create prognostic information by using results of physical examination and blood counts. Various biological and genetic markers also have prognostic value. Deletions of the short arm of chromosome 17 (del [17p]) and/or mutations of the TP53 gene, predict resistance to chemoimmunotherapy and a shorter time to progression, with most targeted therapies. A comprehensive, international prognostic score (CLL-IPI) integrates genetic, biological and clinical variables to identify distinct risk groups of CLL patients.THERAPY: Only patients with active or symptomatic disease, or with advanced Binet or Rai stages require therapy. When treatment is indicated, several options exist for most CLL patients: a combination of venetoclax with obinutuzumab, ibrutinib monotherapy, or chemoimmunotherapy. For physically fit patients younger than 65 (in particular when presenting with a mutated IGVH gene), chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab remains a standard therapy, since it may have curative potential. At relapse, the initial treatment may be repeated, if the treatment-free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using an alternative regimen. Patients with a del (17p) or TP53 mutation are a different, high-risk category and should be treated with targeted agents. An allogeneic SCT may be considered in relapsing patients with TP53 mutations or del (17p), or patients that are refractory to inhibitor therapy.FUTURE CHALLENGES: Targeted agents (ibrutinib, idelalisib, venetoclax, obinutuzumab) will be increasingly used in combination to allow for short, but potentially definitive therapies of CLL. It remains to be proven that they generate a superior outcome when compared to monotherapies with inhibitors of Bruton tyrosine kinase, which can also yield long-lasting remissions. Moreover, the optimal sequencing of drug combinations is unknown. Therefore, CLL patients should be treated in clinical trials whenever possible.

hematology
Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Elise Chapiro,Elodie Pramil,M'boyba Diop,Damien Roos-Weil,Clémentine Dillard,Clémentine Gabillaud,Karim Maloum,Catherine Settegrana,Lucile Baseggio,Jean-François Lesesve,Mélanie Yon,Ludovic Jondreville,Claude Lesty,Frédéric Davi,Magali Le Garff-Tavernier,Nathalie Droin,Philippe Dessen,Caroline Algrin,Véronique Leblond,Jean Gabarre,Simon Bouzy,Virginie Eclache,Baptiste Gaillard,Evelyne Callet-Bauchu,Marc Muller,Christine Lefebvre,Nathalie Nadal,Antoine Ittel,Stéphanie Struski,Marie-Agnès Collonge-Rame,Benoit Quilichini,Sandra Fert-Ferrer,Nathalie Auger,Isabelle Radford-Weiss,Lena Wagner,Sebastian Scheinost,Thorsten Zenz,Santos A Susin,Olivier A Bernard,Florence Nguyen-Khac,the Groupe Francophone de Cytogénétique Hématologique (GFCH),the French Innovative Leukemia Organization (FILO)

DOI: https://doi.org/10.1182/blood.2019001187

IF: 20.3

2019-11-21

Blood

Abstract:B-cell prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying oncogenic mechanisms are poorly understood. Our cytogenetic and molecular assessments of 34 patients with B-PLL revealed several disease-specific features and potential therapeutic targets. The karyotype was complex (≥3 abnormalities) in 73% of the patients and highly complex (≥5 abnormalities) in 45%. The most frequent chromosomal aberrations were translocations involving MYC [t(MYC)] (62%), deletion (del)17p (38%), trisomy (tri)18 (30%), del13q (29%), tri3 (24%), tri12 (24%), and del8p (23%). Twenty-six (76%) of the 34 patients exhibited an MYC aberration, resulting from mutually exclusive translocations or gains. Whole-exome sequencing revealed frequent mutations in TP53, MYD88, BCOR, MYC, SF3B1, SETD2, CHD2, CXCR4, and BCLAF1. The majority of B-PLL used the IGHV3 or IGHV4 subgroups (89%) and displayed significantly mutated IGHV genes (79%). We identified 3 distinct cytogenetic risk groups: low risk (no MYC aberration), intermediate risk (MYC aberration but no del17p), and high risk (MYC aberration and del17p) (P = .0006). In vitro drug response profiling revealed that the combination of a B-cell receptor or BCL2 inhibitor with OTX015 (a bromodomain and extra-terminal motif inhibitor targeting MYC) was associated with significantly lower viability of B-PLL cells harboring a t(MYC). We concluded that cytogenetic analysis is a useful diagnostic and prognostic tool in B-PLL. Targeting MYC may be a useful treatment option in this disease.

Fighting physics: a tough battle

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment

T-cell prolymphocytic leukemia: a single-institution experience

Factors influencing protein tyrosine nitration--structure-based predictive models.

Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene

T‐cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments

From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature

EMT domestic violence knowledge and the results of an educational intervention.

Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia

Diverse two-cysteine photocycles in phytochromes and cyanobacteriochromes

A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia

The construction, calibration and use of thermocouples for measuring body temperature.

Chemoprophylaxis of dental patients with prosthetic joints: a simulation model.

TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy

Effect of the M(s) transformation temperature on the wear behaviour of NiTi shape memory alloys for articular prosthesis.

Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia

Toward novel antiparasitic formulations: Complexes of Albendazole desmotropes and β-cyclodextrin.

Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia

Does a subset of mature T-cell leukemias with features akin to T-cell prolymphocytic leukemia but lacking rearrangement of the TCL1 represent peripheral T-cell lymphoma, NOS in a leukemic phase?

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53